Trial Profile
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Sotigalimab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology
- 22 Jul 2022 Planned End Date changed from 1 Oct 2024 to 1 Oct 2027.
- 22 Jul 2022 Planned primary completion date changed from 1 May 2022 to 1 Nov 2022.